Geriatric Skin Cancer and Concomitant Photosensitivity Drug Utilization

Sokol, Gerald H.; Loftus, Loretta; Oliver, Tim; Ajub, Juliana Cristina Vieira de Freitas Resek; Wright, Gordon; Wenk, David

doi:10.1016/s1879-4068(19)31177-4

Journal of Geriatric Oncology

2019

DOI: 10.1016/s1879-4068(19)31177-4

|View full text |Cite

Geriatric Skin Cancer and Concomitant Photosensitivity Drug Utilization

Gerald H. Sokol¹,

Loretta Loftus²,

Tim Oliver³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The impact of statins on melanoma survival: a systematic review and meta-analysis

McKechnie,

Talwar,

Grewal

et al. 2024

Melanoma Research

View full text Add to dashboard Cite

Statin use may decrease recurrence and improve survival in patients with melanoma. In this systematic review and meta-analysis, we examine the current body of literature concerning the use of statins as an adjunctive therapy in melanoma, Medline, EMBASE, CENTRAL, and PubMed were systematically searched from inception through to April 2023. Studies were included if they compared patients with melanoma receiving and not receiving statin therapy concurrently with their oncologic treatment in terms of long-term oncologic outcomes. The primary outcome was 5-year overall survival (OS). Meta-analyses was performed with DerSimonian and Laird random effects. Risk of bias was assessed with the ROBINS-I and GRADE was used to assess certainty of evidence. From 952 citations, eight non-randomized studies were identified. Included studies were conducted between 2007 and 2022. Random effects meta-analysis of adjusted hazard ratios from three studies suggested an improvement in 5-year OS with statin use with wide 95% confidence intervals (CIs) crossing the line of no effect (hazard ratio 0.87, 95% CI: 0.73–1.04, P = 0.12, I 2 = 95%, very-low certainty). Outcome reporting was heterogeneous across all other oncologic outcomes such that pooling of data was not possible. Risk of bias was serious for seven studies and moderate for one study. This systematic review of studies evaluating the impact of statin use on survival in patients with melanoma found a 13% reduction in risk of death at 5 years from diagnosis – a point estimate suggesting benefit. However, the wide 95% CIs and resultant type II error risk create significant uncertainty.

show abstract

The impact of statins on melanoma survival: a systematic review and meta-analysis

McKechnie,

Talwar,

Grewal

et al. 2024

Melanoma Research

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Geriatric Skin Cancer and Concomitant Photosensitivity Drug Utilization

Cited by 1 publication

References 0 publications

The impact of statins on melanoma survival: a systematic review and meta-analysis

The impact of statins on melanoma survival: a systematic review and meta-analysis

Contact Info

Product

Resources

About